BioSpace News Archive

Monotherapy Confirmed Feasible and Well Tolerated; Clinical Activity Observed in Heavily Pre-treated Patients

100% remission rate in the third dose cohort of 0.75 μCi/kg of Actimab-A (lintuzumab-225Ac) and standard regimen of CLAG-M

Initial results from a recent study indicate that for patients between the ages of 50 and 75, overall survival nearly doubled when patients with myelodysplastic syndrome received allogeneic hematopoietic cell transplantation when compared to other treatments.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the launch of an expanded access program that will allow the company to offer ganaxolone to patients with CDKL5 Deficiency Disorder who were unable to participate in the company’s Marigold Study Phase 3 clinical trial.

Gossamer Bio, Inc. announced that it will host a conference call and webcast for investors and analysts on Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension.

First patient was dosed in pivotal Phase 3 AFFINE study in October 2020

LOTIS 3 interim results highlight potential of Lonca in combination with ibrutinib in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma patients

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced the appointment of Ramzi Benamar to the role of Chief Financial Officer.

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology Annual Meeting.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ATA3219, a next-generation, off-the-shelf, allogeneic CAR T-cell therapy targeting CD1